This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NextGen (NXGN) Introduces New Integrated Care EHR Solution
by Zacks Equity Research
NextGen's (NXGN) newest solution lends support to comprehensive primary care and behavioral health with intellectual and developmental disabilities.
AMN Healthcare (AMN) Stock Moves Up 12.9%: What's Driving It?
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) strong segmental performance and upbeat first-quarter guidance.
Here's Why You Should Hold NextGen (NXGN) Stock For Now
by Zacks Equity Research
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. Intense competition is a headwind.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Nextgen Healthcare (NXGN) Up 4.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nextgen Healthcare (NXGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NextGen (NXGN)-Verato Tie Up to Improve Patient Insights
by Zacks Equity Research
NextGen (NXGN) expects to deliver better insights into patient health history with its latest collaboration with Verato.
NextGen's (NXGN) Integrated Platform to Enhance Tribal Health
by Zacks Equity Research
NextGen's (NXGN) integrated platform was adopted by a community health center in Northern California to meet the health requirements of American Indians/Alaska Natives.
Has Nextgen Healthcare (NXGN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Nextgen Healthcare (NXGN) and PureTech Health PLC Sponsored ADR (PRTC) have performed compared to their sector so far this year.
NextGen Healthcare (NXGN) Beats on Q3 Earnings, Ups FY22 View
by Zacks Equity Research
NextGen Healthcare's (NXGN) fiscal third-quarter earnings reflect strength in both of its revenue sources.
Nextgen Healthcare (NXGN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of 14.29% and 2.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to NextGen (NXGN) Stock Now
by Zacks Equity Research
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. Intense competition is a headwind.
Why Should You Hold Universal Health (UHS) in Your Portfolio?
by Zacks Equity Research
Riding high on strategic measures and a solid solvency level, Universal Health (UHS) holds prospects to reap benefits for investors.
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
by Zacks Equity Research
Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.
Envista (NVST) Gets FDA 510 (k) Approval for N1 Implant System
by Zacks Equity Research
Envista (NVST) noted that the Nobel Biocare N1 system represents a significant step further in patient-centric dental implant solutions.
Abbott (ABT) Diagnostic and Nutrition Arms Grow Worldwide
by Zacks Equity Research
Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
IDEXX's (IDXX) Organic Growth Robust, LPD Revenues Decline
by Zacks Equity Research
IDEXX's (IDXX) global Reference Lab businesses continue to be robust driven by high same-store volume growth with strong gains across testing categories.
Alcon (ALC) Vision Care Sales Grow Despite Supply Disruption
by Zacks Equity Research
Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.
Abbott (ABT) Scales to a 52-Week High: What's Driving It?
by Zacks Equity Research
Strength in Diabetes Care and Diagnostics businesses is driving Abbott's (ABT) top line.
HCA Healthcare (HCA) Up 53.3% in a Year: More Room to Run?
by Zacks Equity Research
HCA Healthcare's (HCA) strategic measures and strong patient volumes will likely lead to better revenues, thus perking up its share price.
LabCorp (LH) to Expand Oncology Portfolio With Latest Buyout
by Zacks Equity Research
LabCorp's (LH) acquisition of PGDx will position the company at the forefront of driving better patient outcomes in oncology.
Here's Why You Should Hold on to Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) strong third-quarter performance and ongoing recovery across its business.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business.
BD (BDX) Partners With Retailers for At-Home COVID-19 Test
by Zacks Equity Research
BD (BDX) collaborates with retail partners and distributors to make the BD Veritor At-Home COVID-19 Test widely accessible.
Tenet Healthcare (THC) Soars 95.8% YTD: More Room to Run?
by Zacks Equity Research
Banking on a solid guidance, enhanced portfolio and strategic measures, Tenet Healthcare (THC) holds enough potential to reap benefits for investors.